Bengaluru: OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE), a multi-modality specialty pharma contract development and manufacturing organization (CDMO), has announced a strategic manufacturing partnership with Formycon AG (FSE: FYB, Prime Standard), an independent biosimilar developer headquartered in Munich, to support the manufacturing of biosimilars for global markets.
Under the agreement, OneSource Specialty Pharma will serve as a strategic manufacturing partner for Formycon, providing integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its state-of-the-art biologics facility in Bengaluru.
The collaboration combines Formycon’s expertise in biosimilar development with OneSource Specialty Pharma’s end-to-end biologics manufacturing capabilities to support Formycon’s biosimilar programs across international markets.
The partnership underscores the shared commitment of both companies to expanding global access to biosimilars through reliable, high-quality and scalable manufacturing. Both organizations aim to support the growing demand for biosimilars by leveraging scientific expertise alongside a sustainable and cost-effective manufacturing model.
OneSource Specialty Pharma is expected to play a key role in delivering this integrated manufacturing approach.
Formycon has built a strong track record in biosimilar development and commercialization, backed by an established product portfolio and a robust development pipeline.
OneSource Specialty Pharma complements these capabilities through its integrated biologics platform, spanning cell line development to commercial fill-finish manufacturing.
The company operates five manufacturing facilities approved by leading global regulatory authorities, including the US FDA and the European Medicines Agency (EMA), and has expertise across biologics, sterile injectables and drug-device combinations.
Also Read: Emcure Takes Full Ownership of Gennova Biopharmaceuticals, Samit Mehta Named CEO
Neeraj Sharma, Managing Director & CEO, OneSource Specialty Pharma, said: “We are delighted to partner with Formycon, one of the world’s leading biosimilar developers with a proven track record of bringing high-quality biosimilars to global markets.
This partnership brings together Formycon’s development expertise and OneSource’s integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide.
It also reinforces our belief that India is uniquely positioned to serve as a global hub for the development and manufacture of world-class biologics.”
Dr. Stefan Glombitza, Chief Executive Officer of Formycon AG, said: “Reliable, scalable and cost-efficient manufacturing is a cornerstone of our FYB4Growth strategy.
By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency. Together, we aim to broaden sustainable global access to life-changing biosimilar therapies.”
The collaboration further strengthens OneSource Specialty Pharma’s position as an integrated biologics manufacturing partner while supporting Formycon’s strategy to expand its biosimilar portfolio through reliable and scalable manufacturing capabilities for global healthcare markets.
